https://www.selleckchem.com/products/ipi-549.html
ction seemed prominent among older patients (aHR 0.65, 95% CI 0.56-0.76 for patients aged ≥70 years; aHR 0.82, 95% CI 0.71-0.96 for patients aged70 years). The reduction in risks of mortality was consistent in subgroup analysis and sensitivity tests. The use of KA supplements seemed to be beneficial for patients with DKD-5-ND; further in-depth analysis of using KA for these patients is warranted. The use of KA supplements seemed to be beneficial for patients with DKD-5-ND; further in-depth analysis of using KA for these patients is
Like
Comment
Share
